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1. INTRODUCTION {#mgg3900-sec-0005}
===============

Autism spectrum disorder (ASD) defines a group of neurodevelopmental disorder (NDD) characterized by impaired social communication, restricted interests and stereotyped and repetitive behaviors (First, [2013](#mgg3900-bib-0005){ref-type="ref"}). Previous studies have shown that de novo variants, including copy number variation, and single nucleotide variants (SNVs) and small insertions and deletions (indels) were strongly associated with ASD patients (Chen, Penagarikano, Belgard, Swarup, & Geschwind, [2015](#mgg3900-bib-0002){ref-type="ref"}; Sebat et al., [2007](#mgg3900-bib-0015){ref-type="ref"}). Dozens of high‐risk ASD genes have been identified from the de novo perspective including *POGZ* (OMIM: 614787), which encodes a domesticated DNA transposase (Bartholomeeusen et al., [2009](#mgg3900-bib-0001){ref-type="ref"}).

*POGZ* encodes a domesticated DNA transposase containing a cluster of multiple C~2~H~2~‐type ZNF domains, a HTH domain, and a DDE domain (Bartholomeeusen et al., [2009](#mgg3900-bib-0001){ref-type="ref"}; Nozawa et al., [2010](#mgg3900-bib-0013){ref-type="ref"}). The expression pattern of *POGZ* in fetal brain tissues suggests that POGZ may play an essential role in early embryonic development (Gudmundsdottir et al., [2018](#mgg3900-bib-0007){ref-type="ref"}; Stessman et al., [2016](#mgg3900-bib-0016){ref-type="ref"}). Previous studies have shown that POGZ is involved in neuronal proliferation, neurite outgrowth, chromatin remodeling, and gene transcription regulation (De Rubeis et al., [2014](#mgg3900-bib-0003){ref-type="ref"}; Gudmundsdottir et al., [2018](#mgg3900-bib-0007){ref-type="ref"}; Hashimoto et al., [2016](#mgg3900-bib-0009){ref-type="ref"}; Nozawa et al., [2010](#mgg3900-bib-0013){ref-type="ref"}). Genotype--phenotype correlation analysis has revealed that likely gene‐disrupting variants in *POGZ* define a potential ASD and ID syndrome (Stessman et al., [2016](#mgg3900-bib-0016){ref-type="ref"}). However, the pathogenicity of de novo missense mutation of *POGZ* in ASD and other related NDDs is not clear. Here, we reported a *POGZ* de novo missense variant identified in an ASD patient. In addition, we comprehensively curated *POGZ* de novo missense variants from large‐scale sequencing studies of neuropsychiatric disorders and provided the evidence of their potential pathogenicity.

2. MATERIALS AND METHODS {#mgg3900-sec-0006}
========================

2.1. Ethical compliance {#mgg3900-sec-0007}
-----------------------

The local institutional review board approved this study. Written informed consent was obtained from the family.

2.2. Patient presentation {#mgg3900-sec-0008}
-------------------------

The male proband (Figure [1](#mgg3900-fig-0001){ref-type="fig"}a) is the first child of his healthy, nonconsanguineous Chinese parents. He was born at term with weight of 3 kg and height of 50 cm. On examination at 5 years and 3 months of age, his weight was 20 kg, height 107 cm (−1 *SD*), and head circumference 52 cm. He was able to raise his head at the age of 3 months, sat without support at the age of 8 months, and walked without support at the age of 12 months. He has hypertonia and delayed fine motor coordination. Speech development was delayed. At the age of 10 months he started speaking his first words, at the age of 38 months he was able to speak his first phrases, at the age of 56 months he could speak complete sentences. His behaviors were characterized by mild attention problems, repetitive behaviors, rare stereotypies, communication difficulties, very little social interaction, temper tantrums, and poor eye contact. He was diagnosed as ASD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) criteria and further confirmed by the Autism Diagnostic Interview‐Revised (ADI‐R). Medical concerns included strabismus in the left eye. There were no reported hyperactivity, gastrointestinal disturbances, sleep disturbances, aggressive behavior, and seizures. No significant facial dysmorphic feature was observed (Figure [1](#mgg3900-fig-0001){ref-type="fig"}a). Brain magnetic resonance imaging performed at the age of 3 years was normal. G‐banded karyotyping revealed normal karyotype (46, XY).

![*POGZ* (GenBank accession number: NM_015100.4) de novo missense variants in neuropsychiatric disorders. (a) Frontal and lateral face photos of the proband reported in this study. (b) Sanger sequencing validated the missense variant is de novo. (c) Immunoblot analysis of *POGZ* expression in peripheral blood lymphocytes of patient and control. Three independent experiments were performed. Data are means ± *SEM*. Differences were statistically significant by Student\'s *t*‐test (\*\*\**p* \< .001). (d) Location distribution of all reported *POGZ* de novo missense variants. The novel de novo missense variant identified in this study is marked with red color. (e) Conservation analysis of all reported *POGZ* de novo missense. The new pathogenic de novo missense variant identified in our study is denoted in red color](MGG3-7-e900-g001){#mgg3900-fig-0001}

2.3. Mutation detection and classification {#mgg3900-sec-0009}
------------------------------------------

Peripheral blood was collected from the proband and parents after obtaining written informed consent. Genomic DNA was extracted from the peripheral blood using a standard proteinase K digestion and phenol‐chloroform method. The single‐molecule molecular inversion probes (smMIP)‐based targeted sequencing method (Wang et al., [2016](#mgg3900-bib-0017){ref-type="ref"}) was performed on the proband. *POGZ* (GenBank accession number: NM_015100.4) variant was validated using Sanger sequencing in both proband and parents.

2.4. Immunoblotting {#mgg3900-sec-0010}
-------------------

EBV‐transformed lymphocyte cell lines from the patient and the controls were lysed in 2× SDS sample buffer (4% SDS, 20% glycerol, 10% 2‐mercaptoethanol, 0.004% bromphenol blue, 0.125 mol/L Tris HCl, pH 6.8) containing a cocktail of protease inhibitors (Millipore, Boston, MA, USA). Proteins were separated by SDS‐PAGE and transferred to polyvinylidene fluoride membranes. Membranes were incubated with anti‐human POGZ polyclonal antibo‐dies (NBP183004, Novus Biologicals, Littleton, CO, USA) overnight at 4°C. The membranes were incubated with secondary antibodies at room temperature for 1h. The signals were detected by using Immobilon Western Chemiluminescent HRP Substrate (Millipore).

3. RESULTS AND DISCUSSION {#mgg3900-sec-0011}
=========================

A rare heterozygous missense mutation in *POGZ* (c.1534C\>A, p.H512N) was identified in a Chinese ASD patient with delayed speech and motor development (Figure [1](#mgg3900-fig-0001){ref-type="fig"}a,b). Sanger sequencing validated this variant in the proband but not in the parents who verified that this variant is de novo. The variant is located in the predicted zinc finger (ZNF) domain, which is the most common DNA‐binding motif (Iuchi, [2001](#mgg3900-bib-0012){ref-type="ref"}). The Combined Annotation Dependent Depletion (CADD) score is 28.9 and multiple in‐silico programs consistently predicted the deleterious effect (Table [1](#mgg3900-tbl-0001){ref-type="table"}). To further confirm the pathogenesis of this mutation, we performed immunoblot using patient‐derived peripheral blood lymphocytes and revealed a drastic decrease in the POGZ (Figure [1](#mgg3900-fig-0001){ref-type="fig"}c) suggesting a loss‐of‐function mechanism of this de novo missense mutation.

###### 

*POGZ* de novo missense variants in neuropsychiatric disorders

  Sample.ID        PMID         Mutation in gDNA (hg19,chr1)   Disorder   NTchange     AAchange   SIFT   Polyphen2   MutationTaster   CADD    ACMG classification
  ---------------- ------------ ------------------------------ ---------- ------------ ---------- ------ ----------- ---------------- ------- ------------------------
  14483.p1         25363768     g.151400436C\>T                ASD        c.941G\>A    p.S314N    T      B           D                14.24   Likely pathogenic
  SD0129.p1        this study   g.151396017G\>T                ASD        c.1534C\>A   p.H512N    D      D           D                28.9    Pathogenic
  14551.p1         25363768     g.151384237T\>C                ASD        c.1790A\>G   p.Y597C    D      D           D                26.1    Likely pathogenic
  1‐02312          26785492     g.151384189T\>C                CHD/DD     c.1838A\>G   p.H613R    D      D           D                25      Likely pathogenic
  2‐1402‐003       28263302     g.151384104G\>C                ASD        c.1923C\>G   p.H641Q    D      D           D                27.5    Likely pathogenic
  NA               25694107     g.151378393C\>T                ASD        c.3118G\>A   p.E1040K   D      D           D                31      Likely pathogenic
  P1381            26582266     g.151378386T\>C                ASD        c.3125A\>G   p.Q1042R   D      D           D                24.8    Pathogenic
  DDD4K.03715      28135719     g.151377883T\>G                ID/DD      c.3628A\>C   p.T1210P   D      B           N                11.9    Likely pathogenic
  NIMH091221_Pro   23911319     g.151377883T\>C                SCZ        c.3628A\>G   p.T1210A   T      B           N                0.048   Uncertain significance

*POGZ* GenBank accession number (NCBI Reference Sequence): NM_015100.4.
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To explore the role of de novo missense variants of *POGZ* in neuropsychiatric disorders, we curated additional eight de novo missense variants (Table [1](#mgg3900-tbl-0001){ref-type="table"}, Figure [1](#mgg3900-fig-0001){ref-type="fig"}d) from seven large‐scale genome‐wide sequencing studies or individual patient reports (Deciphering Developmental Disorders Study, [2017](#mgg3900-bib-0004){ref-type="ref"}; Fukai et al., [2015](#mgg3900-bib-0006){ref-type="ref"}; Gulsuner et al., [2013](#mgg3900-bib-0008){ref-type="ref"}; Hashimoto et al., [2016](#mgg3900-bib-0009){ref-type="ref"}; Homsy et al., [2015](#mgg3900-bib-0010){ref-type="ref"}; Iossifov et al., [2014](#mgg3900-bib-0011){ref-type="ref"}; Yuen et al., [2017](#mgg3900-bib-0018){ref-type="ref"}). De novo missense variants scatteredly located in the protein, no significant cluster was implicated. However, we observed two variants (p.T1210P, p.T1210A) at the same site and two variants (p.E1040K, p.Q1042R) in close proximity located in the DNA‐binding helix‐turn‐helix (HTH) domain. Most of the variants are conserved across species (Figure [1](#mgg3900-fig-0001){ref-type="fig"}e) and predicted to be deleterious (Table [1](#mgg3900-tbl-0001){ref-type="table"}). Notably, four de novo missense mutations are located in (p.H512N, p.Y597C and p.H641Q) or closed to (p.H613R) the predicted ZNF domains. We classified the variants following the standards and guidelines for the interpretation of sequence variants from the American College of Medical Genetics and Genomics (ACMG) (Richards et al., [2015](#mgg3900-bib-0014){ref-type="ref"}) and provided the classification information in Table [1](#mgg3900-tbl-0001){ref-type="table"}. In summary, we identified a novel de novo *POGZ* mutation in an ASD patient and interpreted the potential pathogenicity of de novo missense variants. Our findings will not only benefit the clinical diagnosis and genetic counseling but also provide pathogenic missense variant for the study of POGZ‐related pathogenesis.
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